SOUTH SAN FRANCISCO, Calif., May 7, 2026
TRexBio announced new late-breaking translational and preclinical data supporting TNFR2 agonism as a promising therapeutic strategy for atopic dermatitis (AD) ahead of the upcoming Society for Investigative Dermatology Annual Meeting 2026. The findings strengthen the scientific rationale behind TRB-061, the company’s lead wholly owned TNFR2 agonist, which is currently being evaluated in a Phase 1b clinical trial in patients with moderate-to-severe atopic dermatitis. The presentation will highlight how selective activation of TNFR2 may enhance tissue regulatory T cells (Tregs), restore immune balance, and support tissue repair in inflamed skin without broadly activating inflammatory immune responses, positioning TRB-061 as a potentially differentiated immunoregulatory therapy in the rapidly growing inflammatory dermatology market.
TRB-061 Data Highlight Selective Treg Activation and Immune Regulation
The newly released data demonstrated that patient-derived atopic dermatitis skin samples showed significantly altered tissue Treg programs, supporting the theory that impaired immune regulation contributes directly to chronic inflammation and skin barrier dysfunction in AD. According to TRexBio, detailed translational and functional studies identified TNFR2 as a critical regulator of immune homeostasis in tissue, with selective agonism producing targeted activation and expansion of regulatory T cells while avoiding widespread stimulation of pro-inflammatory immune cells. In vitro experiments showed that TRB-061 selectively enhanced Treg expansion, activation, and suppressive function, reinforcing its mechanism as a precision immunomodulatory therapy rather than a broad immunosuppressive treatment. In addition, non-human primate studies demonstrated pharmacodynamic expansion of tissue-licensed effector Tregs, providing further biological validation for the therapy’s mechanism of action and translational potential in inflammatory skin diseases and other barrier tissue disorders.
TRexBio’s Chief Scientific Officer, Ali Zarrin, stated that the company’s tissue-based Treg research identified altered tissue adaptation programs in lesional skin that point to TNFR2 as an important immune regulator in atopic dermatitis. He emphasized that the combined translational and mechanistic findings support TRB-061’s ability to selectively augment tissue Tregs and potentially address the underlying biology driving chronic inflammation in AD patients. The data will be presented during the SID 2026 ePoster Talk Session focused on late-breaking abstracts, highlighting growing scientific interest in tissue Treg biology and targeted immune regulation as next-generation approaches for autoimmune and inflammatory diseases.
Phase 1b Trial Advances TRB-061 as Potential New AD Therapy
Advertisement
TRB-061 is currently being studied in a randomized, double-blind, placebo-controlled Phase 1b trial involving patients with moderate-to-severe atopic dermatitis. The study includes exploratory pharmacodynamic endpoints evaluating Treg expansion in both blood and skin tissue alongside clinical assessments of disease severity and inflammatory activity. TRexBio expects to report 16-week Phase 1b clinical data during the first half of 2027, an important milestone that could further validate TNFR2 agonism as a novel immunoregulatory pathway for chronic inflammatory diseases.
Atopic dermatitis remains one of the most common chronic inflammatory skin disorders globally, affecting approximately 204 million people worldwide, including up to 20% of children and 10% of adults. Moderate-to-severe disease is often associated with extensive skin involvement, severe itching, systemic immune activation, and major quality-of-life impairment. Although biologic therapies have improved disease management for some patients, a large percentage discontinue currently available treatments due to limited long-term effectiveness, safety concerns, or side effects. TRexBio believes selective TNFR2 agonism may offer a differentiated therapeutic strategy capable of restoring immune balance while minimizing broad immune suppression, potentially creating a new long-term treatment option for inflammatory skin diseases.
TRexBio Expands Tissue Treg-Based Immunology Platform
TRexBio continues to expand its pipeline of tissue Treg-focused therapies using its proprietary Deep Biology Platform, which maps human tissue regulatory T-cell behavior to disease mechanisms in autoimmune and inflammatory disorders. The platform has already generated multiple development-stage candidates targeting novel immunoregulatory pathways, including potential first-in-class and best-in-class therapies across dermatology, gastroenterology, and other immune-mediated diseases. Headquartered in South San Francisco, TRexBio is positioning itself as a key emerging biotechnology company focused on precision immune regulation through tissue Treg biology.
Source: TRexBio press release
